Hard wired
The magic of wireless living is all smoke and mirrors. We may imagine our phone calls and text messages soaring into orbit to ping off the kind of satellites we see in the movies, but 99 percent of digital information travels within an earthbound and tactile system. This global network of cables spanning the oceans and intersecting at key junctures around the world forms a massive foundation of metal, plastic, rubber and optical fiber, all built the old-fashioned way. No wonder it makes news when an undersea cable gets broken or even sabotaged. Here's the breakdown.
The first transatlantic telegram from Queen Victoria to President James Buchanan in 1858 slashed the wait by 95 percent compared to a letter sent via steamliner. That first transoceanic cable — 1,500 tons of copper wrapped in latex, 1,910 miles long — was laid along the seabed from Newfoundland to Ireland, vastly outdoing its humble predecessors across New York Harbor and the British Channel. Some called it 'the eighth wonder of the world.'
Today, data travels at roughly two-thirds the speed of light along the fiber optics that form the core of our modern cables, wrapped in layers of copper, woven steel and polyethylene. Each cable is only about as thick as a garden hose. These 'information superhighways' are buried at the shoreline for security, but lay freely on the ocean floor for most of their reach, sufficiently armored against nature's worst. Most of the time!
Russia and China are prime suspects in recent sabotage attacks on cables in the Baltic Sea and Taiwanese waters, but accidents and natural causes break two to four cables each week. Data is quickly rerouted in most cases, causing little more than a simple refresh for end users. That was not the case off the coast of Africa in 2022, when a cable sabotage near Egypt cut off connectivity for 90 percent of Ethiopia.
If the world's undersea cable systems were to suddenly disappear, only a miniscule amount of this traffic would be backed up by satellite, and the internet would effectively be split between continents.' — Nicole Starosielski, UC Berkeley professor and author of 'The Undersea Network'
That's how far the 565 existing submarine cables would reach, stretched end to end: 919,629 miles. Almost four trips to the moon. Eighty-three more cable projects are planned or under construction, per Telegeography, including Meta's own $10 billion project, nicknamed the 'W' for the pattern it will form to link continents along its 31,068-mile journey. Nearly all are privately owned by consortiums of telecom companies, but Microsoft, Alphabet and Amazon are also getting in the game.
The Polynesian nation was digitally isolated for more than a month after the Hunga Tonga-Hunga Ha'apai volcano erupted under the Pacific Ocean three years ago. A team of 57 people had to install over 56 miles of new undersea cable to get Tonga's internet back online. It's one of 25 islands and countries that still depend on a solitary undersea connection, along with the Marshall Islands, Cook Islands, and Saint-Pierre and Miquelon.
That's how many still lack any mainline cable connections. About 40 percent of the global population still has no internet access, according to research by Edward John Oughton, a geography professor at George Mason University. It would cost nearly half a trillion dollars to connect parts of China, India, Indonesia, Latin America, sub-Saharan Africa, Pakistan and Afghanistan, with $133 billion for cables and towers alone.
Roughly 63 percent of the 11,180 active satellites in orbit belong to Starlink, the global internet provider owned by SpaceX and Elon Musk. The company's high profile in geopolitics has reshaped how people picture internet infrastructure. But its satellites are more like impermanent access points for the transoceanic information highway — 120 fell out of the sky this January, and it wasn't the first time.
This story appears in the April 2025 issue of Deseret Magazine. Learn more about how to subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp.
Yahoo
4 hours ago
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
4 hours ago
- Medscape
Short Fluoroquinolone Regimen Matches Conventional COPD Care
A short-course fluoroquinolone treatment (< 5 days) was as effective as the conventional 7-day course in resolving clinical symptoms of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), while causing fewer adverse events. METHODOLOGY: Researchers conducted a meta-analysis of nine double-blind studies to examine if short-duration is as effective as conventional 7-day duration using fluoroquinolone therapy for AECOPD. The analysis included 3951 adults diagnosed with AECOPD who had not received antimicrobial therapy at the time of diagnosis; of these, 1988 were allocated to short-course treatment and 1963 to long-course treatment with fluoroquinolones. The main outcome was clinical cure at early follow-up, defined as the resolution or improvement of the clinical symptoms of exacerbation. Follow-up evaluations were conducted 3-10 days (early) and 25-30 days (late) after treatment completion. TAKEAWAY: The clinical cure rate within 5-20 days of treatment completion was not significantly different between the short-course and conventional-course fluoroquinolone treatments (odds ratio [OR], 1.00; P = .82). = .82). Similarly, bacteriologic clearance was not significantly different between both treatment regimens at both early and late follow-up ( P = .73). = .73). Compared with long-course therapy, short-course treatment resulted in significantly fewer adverse events (OR, 0.76; P < .05). IN PRACTICE: 'We suggest that the guidelines for the treatment of COPD should recommend a total course of 5 days or less of quinolones regardless of the molecule selected, if we want to avoid antibiotic overconsumption, to slow the emerging curb of the continuous antimicrobial resistance, to improve treatment compliance, and to potentially alleviate the socioeconomic burden of the management of AECOPD,' the authors wrote. SOURCE: This study was led by Salma Messous, PhD, Fattouma Bourguiba University Hospital, Monastir, Tunisia. It was published online on May 24, 2025, in Clinical Therapeutics . LIMITATIONS: This study excluded patients with respiratory or hemodynamic failure; therefore, the results might not be generalizable to all patients. Additionally, a better definition is needed to determine which patients would benefit from antibiotic treatment, as exacerbations are not always caused by pathogenic bacteria. DISCLOSURES: The research did not receive any funding. The authors reported having no conflicts of interest.